论文部分内容阅读
目的评价布地奈德联合β2受体激动剂雾化吸入治疗慢性阻塞性肺疾病(COPD)急性发作的临床疗效。方法随机选自2012年2月至2013年2月就诊于我院的46例COPD患者,将其随机分为观察组与对照组,各23例。对照组采用雾化吸入β2受体激动剂治疗,观察组在对照组基础上联合布地奈德治疗,对两组疗效和安全性进行分析。结果观察组和对照组的总有效率分别为82.6%和39.1%。治疗后血气分析情况差异有统计学意义(P<0.01)。其中观察组有9例出现不良反应,发生率为39.1%,对照组有10例出现不良反应,发生率为43.5%,两组不良反应发生率差异无统计学意义(P>0.05)。结论布地奈德联合β2受体激动剂雾化吸入治疗COPD能使治疗效果得到加强,二者能够有效抑制细菌的生长,且不会增加不良反应发生率,安全系数比较高。
Objective To evaluate the clinical efficacy of budesonide combined with β2 receptor agonist nebulization in the treatment of acute exacerbation of chronic obstructive pulmonary disease (COPD). Methods Forty-six patients with COPD who were treated in our hospital from February 2012 to February 2013 were randomly divided into observation group and control group, with 23 cases in each group. The control group was treated with nebulized β2 receptor agonist. The observation group was treated with budesonide on the basis of the control group, and the curative effect and safety of the two groups were analyzed. Results The total effective rate of observation group and control group were 82.6% and 39.1% respectively. Blood gas analysis after treatment was statistically significant (P <0.01). There were 9 adverse reactions in the observation group, with a incidence rate of 39.1%. In the control group, 10 patients developed adverse reactions with a rate of 43.5%. There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusions The therapeutic effect of budesonide combined with β2 receptor agonist atomized inhalation for the treatment of COPD can be enhanced. Both of them can effectively inhibit the growth of bacteria without increasing the incidence of adverse reactions, and the safety factor is relatively high.